Omic Clinical Trials

278 recruitingLast updated: June 18, 2026

There are 278 actively recruiting omic clinical trials across 43 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Columbus, Ohio, United States, Los Angeles, California, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Omic Trials at a Glance

278 actively recruiting trials for omic are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Not Applicable with 100 trials, with the heaviest enrollment activity in Columbus, Los Angeles, and Houston. Lead sponsors running omic studies include Mayo Clinic, National Cancer Institute (NCI), and Vanderbilt University Medical Center.

Treatments under study

About Omic Clinical Trials

Looking for clinical trials for Omic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Omic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Omic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 278 trials

Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaInvasive Breast Carcinoma+2 more
Mayo Clinic54 enrolled1 locationNCT04521764
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled541 locationsNCT06058377
Recruiting
Phase 3

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled21 locationsNCT07391774
Recruiting
Phase 2

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+2 more
University of Washington22 enrolled2 locationsNCT06518057
Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+3 more
Mayo Clinic230 enrolled1 locationNCT04517838
Recruiting
Not Applicable

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Wake Forest University Health Sciences120 enrolled2 locationsNCT07474090
Recruiting
Not Applicable

Breast Cancer, Reasoning, and Activity Intervention

Breast CancerBreast NeoplasmsAnatomic Stage II Breast Cancer AJCC v8+3 more
Mayo Clinic160 enrolled1 locationNCT04816006
Recruiting
Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Not Applicable

ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression

DepressionAnxietyEconomic Vulnerability+1 more
University of Massachusetts, Worcester600 enrolled1 locationNCT06295250
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)32 enrolled10 locationsNCT05673200
Recruiting
Phase 3

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
City of Hope Medical Center80 enrolled3 locationsNCT06763328
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting

Natural History Study of Synucleinopathies

Multiple System AtrophyParkinson DiseaseDementia With Lewy Bodies+5 more
NYU Langone Health800 enrolled8 locationsNCT01799915
Recruiting
Not Applicable

Trial of Precision Medicine in Emergency Departments

Pharmacogenomic Drug Interaction
University of Florida1,200 enrolled3 locationsNCT06448091
Recruiting

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)Epigenomics+1 more
Central Hospital, Nancy, France400 enrolled1 locationNCT06778317
Recruiting
Not Applicable

Feasibility of Lower-Body EMS Resistance Training in Postmenopausal Women

Body CompositionResistance ExercisePost Menopausal+1 more
Seoul National University16 enrolled1 locationNCT07628790
Recruiting
Not Applicable

Recovery Legal Care Clinical Trial

Injury TraumaticFirearm InjuryEconomic Problems
University of Chicago500 enrolled1 locationNCT06618794